key: cord-0800539-javgksv1 authors: Chirumbolo, Salvatore title: Vaccination hesitancy and the “myth” on mRNA‐based vaccines in Italy in the COVID‐19 era: Does urgency meet major safety criteria? date: 2021-03-25 journal: J Med Virol DOI: 10.1002/jmv.26922 sha: dd556df049c9778dca648e18cbdb0d7ec340c081 doc_id: 800539 cord_uid: javgksv1 Coronavirus disease 2019 (COVID‐19) vaccination campaign in Italy has started with a huge perplexity about vaccine efficacy, vaccine‐borne adverse effects and vaccine clinical trial studies. In this commentary I tried to elucidate these issues, which represent a fundamental topic to be thoroughly addressed in COVID‐19 pandemic. Coronavirus disease 2019 (COVID-19) pandemic still stands as a huge health concern, reaching more than 2.61 millions of cases and 90,618 victims worldwide on February 5th, 2021. To face at pandemic emergency, any Government is engaging a gigantic struggle against infectious contacts. Nations are currently adopting lockdown and several restrictions measures against usual social habits but are more frequently asking for crucial and urgent decisions from politics in setting the widest vaccination campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [1] [2] [3] Anyway, despite vaccination emergency is somewhat felt as a mandatory commitment to dampen infectious contacts, reduce COVID-19 hospitalization and come back to previous life customs, vaccination hesitancy, particularly on the more straightforward messenger RNA (mRNA)-based vaccines, still represents a fundamental concern. In Italy, particularly for people usually refusing flu vaccines, hesitancy towards novel vaccine mRNA formulas is closely associated with increasing doubts on vaccination in general. 4 By the way, public and institutional information about the many safety issues in the vaccination campaign are particularly weak in their persuasive potential. Questions were raised, for the many vaccine formulations available to date, on who could be vaccinated or not without any major health risk, such as elderly people with co-morbidities or people living with HIV. 5, 6 The great complexity of topics regarding COVID-19 vaccines should deserve particular attention, as it deals with a global extent. Experts in the field focus their major concerns on allergy side effects and vaccination efficacy. For example, the ARIA-EAACI position paper about possible adverse effects caused by COVID19 vaccination, such as hypersensitivity reactions, recently stated that, as regarding the vaccine BNT162b2, several cases of anaphylaxis occurred, but the Committee concluded that vaccination, held to overcome pandemic, is much more crucial than risking for anecdotic episodes of severe anaphylaxis. 7 This position statement may sound as a cynic consideration about safety, yet the urgency in defeating COVID-19 pandemic is considered of the utmost importance. The critical controversy between urgency in dampening SARS-CoV-2 infections and vaccine reliability is the real matter of debate about vaccination. The mRNA based BNT162b2 vaccine has been recently questioned about its efficacy against SARS-CoV-2 variants, despite very recent reports showed neutralization efficacy on N501Y nCOV19 mutant and the UK variant. 7-10 Actually, mRNA based vaccines represent a straightforward tool against infectious diseases and pandemic. [11] [12] [13] [14] Widespread information about novel formulations, as mRNAbased vaccines, is particularly crowded and inflated by non reviewed opinions and the debate can generate even alarming fakes about vaccination due to anecdotal news. As a matter of fact, people are commonly impressed by the emphasized tale of single, sporadic cases of adverse effects, without being correctly informed about the actual risk to undergo a severe damage upon a medical intervention. Estimating a risk to meet an adverse drug reaction (ADR) to vaccines, even by the mainstream information, is particularly crucial to warrant for a consolidated awareness of vaccination primacy among people. Whereas the US CDC reported 6 cases of anaphylaxis due to COVID-19 mRNA vaccines on 270,001 doses (Dec 19th, 2020), suggesting a risk <0.0023%, citizens could be ensured that this risk is really negligible in medical practice. Actually, undergoing a surgical intervention has a much higher mortality rate (0.71%) and 0.17% in elective surgery (10 times higher during emergency). 15 On the contrary, the most correct information about vaccination is quite scanty in Italy, which prefers to mythologize COVID-19 vaccines as undisputable tools for health and well being, without any expanded debate about experts. 16 Vaccine myth as well as vaccine distrust, are both regrettable attitudes. A proper behavior towards vaccination is trusting vaccination as a medical expert practice and an outstanding and straightforward way to overcome infectious diseases. Trusting medicine should be a commonly positive feeling. Usually, a patient does not exhibit such burden of doubts and refusal against a simple therapic drug, despite even a simple pill, such as an antibiotic, may have adverse effects. The atavistic fear against vaccines dates back to Jenner, in the XVIII century, therefore, as people are convinced about vaccines as a source of "modified" harmful pathogens (yet, always pathogens) the concern of public vaccination is still far to be fully reassured. 17 Therefore, which is the best approach to overcome this concern? To be much more properly and clearly informed. In Italy, correct information about mRNA-based vaccines is scanty. Urgency in vaccination should not dampen the scientific debate. Both BNT-162b2, produced by Pfizer-BioNTech and mRNA-1273 by Moderna, are simple molecules of ribonucleic acid, modified with pseudo-uridine (ΨU) and included in lipid nano-particle (LNPs) vehicles. RNA is endowed to be rapidly translated into nonfunctional SARS-CoV-2 S (spike) proteins, i.e. an S-proteins in a stable closed structure, 18 so to trigger the immune response in the host without inducing damage due to its activity on the ACE2 receptor. 18, 19 As reported few lines ago, recent data are supporting the idea that these vaccine formulations have possible and significant adverse effects, particularly by highlighting the worrisome concern that anaphylaxis due to BNT162b1 vaccine accounts to 1:45,000, a ratio much higher than the usual allergic side effect percentage due to commonly used vaccines, that is, 1:1,000,000. 20 Estimated percentages need reappraisal on a global scale, however. Briefly speaking, it is correct to state that some components should deserve caution, due to their assessed allergenicity. Lipids used for LNPs may elicit allergy-related and immune responses. 21, 22 High molecular weight poly-ethylene-glycol, present in BNT162b2 as ALC0159 (2-[(polyethylene glycol)-2000]-N,N-di-tetradecyl-acetamide) is considered the leading cause of vaccine-caused anaphylaxis. 23 PEG presence, particularly in LNPs, is not yet a novelty in pharmacological science, anyway. PEG is contained in many commonly used medicines. Table 1 lists some major FDA approved drugs for human therapy, which contain PEG and may cause anaphylaxis. Considering that PEG is particularly frequent in several therapic formulas, the simple information about the anaphylactic potential of PEG should not exacerbate the civil debate about vaccines, at least because a huge deal of PEGylated therapic drugs is commonly used in the medical healthcare without bursting raw popular outcries. More correct information to ensure citizens about vaccine safety is mandatory, therefore. Considering the small number of anaphylaxis cases in US by CDC reports and the amount of ADRs to vaccine in US (101) on 158,000 vaccinated people, 24 the relative risk we calculated in our labs (SPSS software v 24.1) to meet a PEG-related anaphylaxis should be around 0.03, a very low value, even assessing previously reported evidence. 25 Yet, reports exist showing that PEG-caused anaphylaxis may be particularly dramatic for subjects, 23 and this may burst a serious public health concern. In Italy, no clear warning about PEG-mediated ADRs regarding RNA-based vaccines has been ever forwarded by Government in- later, were SARS-CoV-2 RT-PCR positive but seven of them loss the specific IgGs. [34] [35] [36] So, besides to ADRs, the biggest burden of concerns regarding mRNA-based vaccines is the complete lacking of prospective studies. This can be comprehensible, if we would like to shut down pandemic worldwide: vaccines are an undelayable emergency need. Two main issues should make highly debating the need to set a prospective survey. The LNP-encapsulated mRNA has been never attempted before as a vaccine tool and none can say anything about the consequences of introducing RNA inside the body. The increased ability of pseudouridinylated BNT162b2 mRNA or of mRNA1273 to be translated with relatively high efficiency, may cause endoplasmic Speed versus efficacy: quantifying potential tradeoffs in COVID-19 vaccine deployment A public health COVID-19 vaccination strategy to maximize the health gains for every single vaccine dose Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases Associations of COVID-19 risk perception with vaccine hesitancy over time for Italian residents When epidemics collide: why people with HIV may have worse COVID-19 outcomes and implications for vaccination Age and frailty in COVID-19 vaccine development Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization mRNA vaccine: a potential therapeutic strategy Selfamplifying replicon RNA vaccine delivery to dendritic cells by synthetic nanoparticles mRNA vaccines-a new era in vaccinology Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from ebola virus disease Surgical mortality-an analysis of all deaths within a general surgical department Vaccinology in the post-COVID-19 era Public fear of vaccination: separating fact from fiction C4591001 clinical trial group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine COVE Study Group Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Severe allergic reactions to the COVID-19 vaccine -statement and practical consequences Hypersensitivity and nanoparticles: update and research trends Nanoparticles and the immune system Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients Vaccination and anaphylaxis A simple method for estimating relative risk using logistic regression Triumphs and tribulations of COVID-19 vaccines: Lessons to be learned from smallpox epidemics in the 1700s Vaccine hesitancy in COVID-19 times. An update from Italy before flu season starts Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: a cross-sectional survey Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: a survey Will COVID-19 vaccines save lives? Current trials aren't designed to tell us Doctors call for investigation into allegations of ethical abuse in covid-19 vaccine trial Immune response to COVID-19 infection: a double-edged sword Who is really at risk for anaphylaxis due to COVID-19 vaccine? Vaccines Anaphylactic reactions to novel mRNA SARS-CoV-2/ COVID-19 vaccines A prospective study on rapidly declining SARS-CoV-2 IgG antibodies within one to three months of testing IgG positive: can it lead to potential reinfections? Cureus The coronavirus spike protein induces endoplasmic reticulum stress and upregulation of intracellular chemokine mRNA concentrations Cytokines and chemokines in SARS-CoV-2 infections-therapeutic strategies targeting cytokine storm A method for prioritizing risk groups for early SARS-CoV-2 vaccination, by the numbers. medRxiv http://orcid.org/0000-0003-1789-8307